Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Fudan University100 enrolled

Overview

The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.

We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer. The study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Colorectal Cancer

Interventions

tac + folfox4DRUG

tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4

folfox4DRUG

folfox4 will be done within 28 days after liver resection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \<= 75 years * resectable liver metastasis * remnant liver volume \>= 70% * without other organ metastasis or peritoneum metastasis * without contradiction of cardiac and pulmonary diseases Exclusion Criteria: * age \> 75 years * unresectable liver metastasis * remnant liver volume \< 50% * with other organ metastasis or peritoneum metastasis * with contradiction of cardiac and pulmonary diseases

Locations (1)

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

progression free survival

Time frame: 5 years after operation

Secondary Outcomes

overall survival

Time frame: 5 years after operation

Central Contacts

jianmin xu, MD, PHD

CONTACT

008613501984869 xujmin@yahoo.com.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.